PMID- 35547289
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 8
IP  - 52
DP  - 2018 Aug 20
TI  - Anti-tumor effect of HOTAIR-miR-613-SNAI2 axis through suppressing EMT and drug 
      resistance in laryngeal squamous cell carcinoma.
PG  - 29879-29889
LID - 10.1039/c8ra04514c [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the main pathological type of 
      laryngeal cancer, which attacks the head and neck. Our present study aims to 
      investigate the effect of long non-coding RNA (LncRNA) HOX transcript antisense 
      RNA (HOTAIR) on epithelial mesenchymal transition (EMT) and drug resistance in 
      LSCC. Firstly, the level of HOTAIR was found to be overexpressed in LSCC tissues 
      compared with normal healthy tissues. Then, increased EMT and drug resistance 
      were suppressed by specific HOTAIR shRNA effectively in LSCC cell lines. Besides, 
      miR-613 was predicted to be a target of HOTAIR through bioinformatics analysis. 
      Meanwhile, we found that a down-regulated level of miR-613 could be increased by 
      HOTAIR shRNA and suppressed by LncRNA HOTAIR transfection in LSCC cells. The 
      targeting relationship between miR-613 and HOTAIR was further demonstrated by a 
      luciferase report assay. What is more, the inhibiting effect of HOTAIR shRNA on 
      EMT and drug resistance was obviously abolished by the miR-613 inhibitor. 
      Moreover, SNAI2, a critical regulator of EMT, was predicted as a target of 
      miR-613 through bioinformatics analysis and luciferase report assays. As 
      expected, the level of SNAI2 could be suppressed by HOTAIR shRNA and increased by 
      the miR-613 inhibitor. Additionally, we discovered that SANI2 shRNA had similar 
      inhibiting effect on EMT and drug resistance with HOTAIR shRNA in LSCC cells. 
      Finally, the in vivo experiment further demonstrated that HOTAIR shRNA restricted 
      tumor growth, EMT and drug resistance. Additionally, HOTAIR shRNA transfection 
      could also increase the level of miR-613 and decrease the level of SNAI2 in vivo. 
      Taken together, our research for the first time revealed the effect of the 
      HOTAIR-miR-613-SNAI2 axis on EMT and drug resistance in LSCC, providing new 
      targets for LSCC diagnosis and treatment.
CI  - This journal is (c) The Royal Society of Chemistry.
FAU - Zhou, Jing-Chun
AU  - Zhou JC
AD  - Department of Otorhinolaryngology, The Second Clinical Medical College of Jinan 
      University, Shenzhen People's Hospital No. 1017 Dongmen North Road, Luohu 
      District Shenzhen Guangdong 518020 China kezhaoyang2018@yeah.net 
      +86-755-25533018.
FAU - Zhang, Jing-Jing
AU  - Zhang JJ
AD  - Department of Otorhinolaryngology, Peking University Shenzhen Hospital Guangdong 
      518036 China.
FAU - Ma, Wei
AU  - Ma W
AD  - Translational Medicine Collaorative Innovation Center, The Second Clinical 
      Medical College of Jinan University, Shenzhen People's Hospital Guangdong 518020 
      China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of Otorhinolaryngology, The Second Clinical Medical College of Jinan 
      University, Shenzhen People's Hospital No. 1017 Dongmen North Road, Luohu 
      District Shenzhen Guangdong 518020 China kezhaoyang2018@yeah.net 
      +86-755-25533018.
FAU - Ke, Zhao-Yang
AU  - Ke ZY
AUID- ORCID: 0000-0002-7736-8175
AD  - Department of Otorhinolaryngology, The Second Clinical Medical College of Jinan 
      University, Shenzhen People's Hospital No. 1017 Dongmen North Road, Luohu 
      District Shenzhen Guangdong 518020 China kezhaoyang2018@yeah.net 
      +86-755-25533018.
FAU - Ma, Ling-Guo
AU  - Ma LG
AD  - Department of Otorhinolaryngology, The Second Clinical Medical College of Jinan 
      University, Shenzhen People's Hospital No. 1017 Dongmen North Road, Luohu 
      District Shenzhen Guangdong 518020 China kezhaoyang2018@yeah.net 
      +86-755-25533018.
LA  - eng
PT  - Journal Article
DEP - 20180823
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC9085281
COIS- The authors have declared that no competing interest exists.
EDAT- 2018/08/23 00:00
MHDA- 2018/08/23 00:01
PMCR- 2018/08/23
CRDT- 2022/05/13 11:11
PHST- 2018/05/27 00:00 [received]
PHST- 2018/07/23 00:00 [accepted]
PHST- 2022/05/13 11:11 [entrez]
PHST- 2018/08/23 00:00 [pubmed]
PHST- 2018/08/23 00:01 [medline]
PHST- 2018/08/23 00:00 [pmc-release]
AID - c8ra04514c [pii]
AID - 10.1039/c8ra04514c [doi]
PST - epublish
SO  - RSC Adv. 2018 Aug 23;8(52):29879-29889. doi: 10.1039/c8ra04514c. eCollection 2018 
      Aug 20.